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Background: Alectinib is an approved treatment for anaplastic lymphoma kinase (ALK)positive patients with advanced non-small-cell lung cancer. Despite positive supporting clinical
data, there is a lack of real-world information on the usage and patient outcomes of those treated
with alectinib post-crizotinib progression.
Methods: Participating oncologists (N=95) in the USA were recruited from an online physician
panel to participate in a retrospective patient chart review. Physicians randomly selected eligible
patients (ie, patients who progressed on crizotinib as their first ALK inhibitor and were treated
with alectinib as their second ALK inhibitor), collected demographics and clinical history from
their medical charts, and entered the data into an online data collection form.
Results: A total of N=207 patient charts were included (age: 60.1±10.4 years; 53.6% male).
The patients in our sample were older (median age of 60 vs 53 years), were more likely to be
current smokers (12% vs 1%), had better performance status (45% vs 33% had an Eastern
Cooperative Oncology Group [ECOG] of 0), and were less likely to have an adenocarcinoma
histology (83% vs 96%) relative to published clinical trials. The objective response rate was
higher than in clinical trials (67.1% vs 51.3%, respectively) as was the disease control rate
(89.9% vs 78.8%, respectively), though it varied by race/ethnicity, ECOG, and prior treatment history. Discontinuation (0.0%) and dose reductions (3.4%) due to adverse events were
uncommon in alectinib.
Conclusion: Patients using alectinib post-crizotinib in clinical practice are older, more racially/
ethnically and histologically diverse than patients in published trials. Real-world response rates
were high and similar to those reported in clinical studies, though there is some variation by
patient characteristics. Alectinib was well tolerated in clinical practice as reflected by the rates
of discontinuation, dose reductions, and dose interruptions.
Keywords: alectinib, anaplastic lymphoma kinase, non-small-cell lung cancer, treatment patterns, outcomes, ALK inhibitor, ALK+
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An estimated 220,000 adults were diagnosed with lung and bronchus cancer in the
USA in 2015, representing 13% of all new cancer cases.1 Non-small-cell lung cancer
(NSCLC) accounts for ~80%–85% of all cases of lung cancer, and is the most common cause of death in men and second only to breast cancer in women.2 Prognosis is
poor for patients with metastatic disease, with the median survival ,1 year because
of delays in diagnosis.3,4
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Treatment of NSCLC is guided by disease stage, histology, and mutation status. Surgery is the most common treatment for early-stage localized disease, whereas multimodal
therapy remains the norm for patients with locally advanced
disease.5 Approximately 40% of patients with NSCLC present
with metastatic or locally advanced disease, underscoring the
importance of identifying therapeutic regimens that may benefit
this large patient population. Combination chemotherapy,
usually platinum-based, has historically been the first-line
therapy of choice for advanced NSCLC among patients without
driver mutations.6–8 Newer agents, such as programmed cell
death-1 and programmed cell death ligand-1 inhibitors,
have been more recently evaluated in clinical trials for the
treatment of NSCLC and several other types of cancer.9–11
Over the last decade, a variety of targeted therapies have
been developed for the treatment of advanced or metastatic
NSCLC in patients with driver mutations. Indeed, anaplastic
lymphoma kinase (ALK) inhibitors represent a promising
potential target for antitumor therapy,12–14 with ~2%–7% of
patients with NSCLC being ALK positive.7,15 Crizotinib was
identified as the first potent inhibitor of ALK in experimental
cancer models; 16 clinical data have suggested superior
response and longer progression-free survival for patients
treated with crizotinib relative to chemotherapy.17–20
Despite these efficacy results, almost all patients ultimately develop resistance to crizotinib within 1–2 years,
with the central nervous system (CNS) being a frequent site
of progression.21–24 The recently available second-generation
ALK inhibitors (eg, ceritinib, alectinib, brigatinib) and thirdgeneration ALK inhibitors (eg, lorlatinib) have been found
to provide significant benefits for patients who experience
crizotinib progression.25,26 Of the second-generation ALK
inhibitors, alectinib is the only one that is not exported
out of the CNS because of it not being a p-glycoprotein
substrate,25–27 and several clinical studies28–31 have shown
alectinib to be highly active, especially in patients with
brain metastases and CNS disease. Further, alectinib is well
tolerated among crizotinib-resistant patients.28–31 However,
little real-world data exist on the usage and outcomes of
patients treated with alectinib after crizotinib progression.
The aim of the present study is to examine the real-world
treatment patterns and clinical outcomes of patients with
ALK+ NSCLC who have progressed on crizotinib and were
treated with alectinib as their second ALK inhibitor.

Methods
Data source
A retrospective patient chart review study was conducted to
meet the objectives described above. Participating oncologists
76
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were recruited from the Medefield physician panel (http://
www.medefield.com/). The Medefield panel is an opt-in
panel in which physicians join with the understanding that
they will complete periodic surveys. All panel physicians
in the USA have their credentials validated with American
Medical Association.
Potential physician respondents were emailed an invitation
to participate in the study. Physicians who provided informed
consent were screened for eligibility. Physicians’ inclusion
criteria include board-certified or board-eligible oncologist,
in practice for at least 5 years but no more than 25 years,
personally involved in the treatment decisions of patients with
NSCLC, and have seen at least 1 NSCLC ALK+ patient in
the past year. Physicians who met inclusion criteria were then
asked to select between 1 and 5 of their patient charts that met
the following eligibility criteria: $18 years, diagnosed with
ALK+ NSCLC (tumors harboring a rearranged ALK gene/
fusion protein), and experienced disease progression while
on crizotinib (as their first ALK inhibitor). ALK+ status was
determined by the responding physician based on results available in the patient chart. It was desired to have a minimum of
12-month follow-up from time of initial disease progression
on crizotinib or until death (if ,12 months of follow-up exist).
Patients who participated in an NSCLC-related clinical trial
prior to crizotinib and alectinib were excluded.
Using the data available from each medical chart, the
physician collected the demographics, health history, health
care resource use, and treatment information for each patient.
Data were pulled from notes from physical examinations,
laboratory data, imaging data, prescription data, and nurse
records, as appropriate.

Ethics
The study protocol and data collection form were reviewed
by an independent institutional review board (Pearl IRB,
Indianapolis, IN; Protocol #: 16-033202) and the study was
granted exemption status. The IRB reviewed the documents
submitted for exemption determination in accordance to the
US Food and Drug Administration 21 CFR 56.104 and the
Department of Health and Human Services 45 CFR 46.101
regulations.. The exemption was approved under the exempt
review category 45 CFR 46.101(b) category 4.
Patient written informed consent to review the medical
records was not required by the IRB as no personally identifiable patient information was collected. Only anonymous
patient data were collected and results were only reported in
aggregate. Physicians provided consent for participating in the
study and written informed consent was required from each
responding physician, before participating in the study.
OncoTargets and Therapy 2018:11
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Data from a total of N=207 patient charts who used alectinib
as their second ALK inhibitor were collected from N=95
physicians.
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Study measures
Physician demographics: Physicians provided information
as to their age, sex, and practice characteristics (years in
practice, setting, and patient load).
Patient demographics: Physicians provided information
related to the age, sex, and employment status of each patient.
General health history: Height and weight (to convert
to body mass index [BMI] category), smoking history, and
comorbidities (to calculate a Charlson comorbidity index)
were assessed.
NSCLC history: The date of diagnosis, stage at diagnosis,
histology, current performance status (Eastern Cooperative
Oncology Group [ECOG]), and the number/location/date of
metastases were captured.
Treatment history: Treatments used prior to and after
crizotinib, including their duration, were captured. Reasons
for discontinuation of each therapy were captured along with
the presence and reasons for dose modifications. The presence of adverse events was captured along with treatments
related to brain/CNS metastases.
Clinical outcomes: Best response (complete response
[CR], partial response [PR], stable disease [SD], or progression) was captured for each treatment based on the interpretation of the treating physician using the data contained
within the medical chart. The study did not mandate that
any specific criteria, such as RECIST v1.1, were to be used
in this assessment. For the purposes of this study, objective
response rate (ORR) was defined as the proportion of patients
achieving a best response of CR or PR. Disease control rate
(DCR) was defined as the proportion of patients achieving
a best response of CR, PR, or SD.
Health care resource use: The number of hospitalizations, emergency room visits, and office visits was captured.
Health care resource use specific to adverse events was
also assessed.

Statistical analysis
Physician and patient characteristics, response rates, and
safety/tolerability were reported descriptively using frequencies and percentages for categorical variables and means and
standard deviations for continuous variables. Differences
in response rates across patient characteristic strata were
compared using chi-square tests.
OncoTargets and Therapy 2018:11
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Results
Physician characteristics
A total of N=95 physicians contributed patient charts; N=47
(49.5%) specialized in hematology/oncology and N=48
(50.5%) specialized in medical oncology (Table 1). Physicians were predominantly male (81.1%), with a mean of
14.6 years (SD =6.4) in practice. The most common practice
setting was private practice (46.3%) followed by an academic
hospital/medical center (35.8%).

Real-world vs clinical trial patient
characteristics
Descriptive comparisons were then made between our
study and available clinical trial results (Table 2).28,29 Key
differences observed between our study and clinical trial
populations included age (median age of 60 vs 53 for our
study and the pooled clinical trial samples, respectively),
gender (54% vs 44% male, respectively), and performance
status (45% vs 33% had an ECOG of 0). Both our study
and clinical trial samples had similar percentages of Asian
patients (18% vs 19%). Patients in our study were more
likely to be a current smoker (12% vs 1%), less likely to
have an adenocarcinoma histology (83% vs 96%), and were
less likely to have presented with brain metastases (12% vs
60%) relative to clinical trial samples.
Comparisons were also made between alectinib best
overall responses rates in our study and clinical trial data
(Table 3). Among the full sample (N=207 alectinib patients),
Table 1 Characteristics of the physician sample treating patients
with alectinib post-crizotinib progression (N=95)
Characteristics

Total sample
(N=95)

Physician gender
Male (%)
Female (%)
Physician age
,40 years (%)
41–50 years (%)
51–60 years (%)
61–70 years (%)
Physician specialty
Medical oncology (%)
Hematology/oncology (%)
Years of practice in specialty
Mean ± Standard deviation
Median (min–max)
Primary clinical practice
Private practice (%)
Academic hospital/medical center (%)
Nonacademic hospital/medical center (%)
Comprehensive cancer center (%)

77 (81.1)
18 (18.9)
19 (20.0)
49 (51.6)
22 (23.2)
5 (5.3)
47 (49.5)
48 (50.5)
14.6±6.4
15 (5.0–30.0)
44 (46.3)
34 (35.8)
10 (10.5)
7 (7.4)
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Table 2 Differences in patient characteristics between clinical trial samples and the current study sample among those using alectinib
post-crizotinib progression
Characteristics

Alectinib group
in Ou et al28

Alectinib group
in Shaw et al29

Pooled analysis
in Yang et al30

Alectinib group
in study sample

N
Patient age (years)
Mean ± Standard deviation
Median (min–max)
Sex
Male (%)
Female (%)
Race/ethnicity
Non-Hispanic White/Caucasian (%)
Asian (%)
Non-Hispanic Black/African American (%)
Hispanic (%)
Other (%)
Smoking status
Current smoker (%)
Former smoker (%)
Never smoker (%)
Passive (second-hand) smoker (%)
Unknown (%)
NSCLC histological subtype
Adenocarcinoma (%)
Epidermoid or squamous cell carcinoma (%)
Large cell carcinoma (%)
ECOG at crizotinib initiation
0 (%)
1 (%)
2 (%)
3 (%)
Treatments prior to crizotinib
Chemotherapy (%)
Baseline CNS metastases
Follow-up period, months (min–max)

138

87

225

207

51.5±11.1
52.0 (22.0–79.0)

N/A
54.0 (29.0–79.0)

N/A
53.0 (22.0–79.0)

60.1±10.4
60 (25–86)

61 (44)
77 (56)

39 (45)
48 (55)

100 (44)
125 (56)

111 (53.6)
96 (46.4)

93 (67)
36 (26)

73 (84)
7 (8)

166 (74)
43 (19)
4 (2)

9 (7)

7 (8)

12 (5)

113 (54.6)
37 (17.9)
29 (14.0)
25 (12.1)
3 (1.5)

3 (2)
39 (28)
96 (70)
0 (0)
0 (0)

0 (0)
33 (38)
54 (62)
0 (0)
0 (0)

3 (1)
72 (32)
150 (67)
0 (0)
0 (0)

24 (11.6)
86 (41.6)
81 (39.1)
13 (6.3)
3 (1.5)

133 (96)
2 (1)
3 (2)

82 (94)
5 (6)

215 (96)
10 (4)

172 (83.1)
11 (5.3)
16 (7.7)

44 (32)
81 (59)
13 (9)
0 (0)

30 (35)
48 (55)
9 (10)
0 (0)

74 (33)
129 (57)
22 (10)
0 (0)

94 (45.4)
84 (40.6)
18 (8.7)
10 (4.8)

110 (80)
83 (61)
3.9–14.1 (primary)
8.7–18.9 (updated)

64 (74)
52 (60)
1.1–13.6 (primary)
1.1–19.9 (updated)

174 (77)
136 (60)
N/A

45 (22)
25 (12.1)
0.0–10.0

Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; N/A, not applicable; NSCLC, non-small-cell lung cancer.

the ORR was higher than in clinical trials (67.1% vs
51.3%, respectively) as was the DCR (89.9% vs 78.8%,
respectively).
Best overall response rates in the overall alectinib subsample were then compared across various patient characteristic strata (Table 4). As reported above, best overall
response rates were consistent, and in some cases higher than
those reported in prior clinical trials.28,29 Although response
did not differ by physician characteristics or patient age,
ORR was highest among Asian respondents (89.2%) vs
47.4% among non-Asian/non-White respondents (P,.05).
These findings are consistent with those reported in clinical
trials.28,29 Former/passive/never smokers exhibited higher
response rates relative to current smokers (ORR =68.3%
vs 58.3%) but this difference was not significant (P=0.07).
No differences were observed by level of BMI (P=0.81).
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Better functional status, as assessed by ECOG performance
score, was associated with better response (ORR =71.6%
for ECOG 0–1 vs 30.0% for ECOG 2+; P,0.05). Finally,
ORR was similar between those with and without prior
chemotherapy (65.9% vs 67.5%, respectively); however,
rates of SD were higher (25.8% vs 11.4%) and rates of PD
were lower (6.7% vs 22.7%) for those without prior chemotherapy (P,0.05).

Dose modifications
The median dose for the patients in this study was 600 mg
twice daily. Discontinuations were the most common category of dosage modification. Among those who used
alectinib, 14.0% of patients (N=29) discontinued the drug,
whereas only 4.3% (N=9) had their dose reduced; and only
one patient experienced a dose interruption (N=1; 0.5%

OncoTargets and Therapy 2018:11
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Table 3 Differences in best overall systemic response rate between clinical trial samples and the current study sample among those
using alectinib post-crizotinib progression
Types of response rate

Alectinib group
in Ou et al28
(response-evaluable
population)

Alectinib group
in Shaw et al29
(primary analysis)

Pooled analysis
in Yang et al30

Alectinib group
in study sample

N
Complete response (%)
Partial response (%)
Stable disease (%)
Progressed disease (%)
Unknown/indeterminate (%)
Objective response rate (%)
Disease control rate (%)

122
0 (0.0)
61 (50.0)
35 (28.7)
22 (18.0)
4 (3.3)
61 (50.0)
96 (78.7)

67
0 (0.0)
35 (52.2)
18 (26.9)
11 (16.4)
3 (4.5)
35 (52.2)
53 (79.1)

189
0 (0.0)
97 (51.3)
52 (27.5)
N/A
N/A
97 (51.3)
149 (78.8)

207
14 (6.8)
125 (60.4)
47 (22.7)
21 (10.1)
0 (0.0)
139 (67.1)
186 (89.9)

Abbreviation: N/A, not applicable.

[Table 5]). Of the dose discontinuations, N=12 (41.4%) were
due to disease progression, 9 (31.0%) were due to death, N=5
(17.2%) were due to patient request, and N=3 (10.3%) were
due to other reasons (none were due to adverse events).

Safety and tolerability
There were no dose discontinuations or dose reductions due
to adverse events among the patients in this study. Of the
dose reductions, N=7 (3.38%) were due to adverse events;

Table 4 Differences in best overall systemic response rate across patient characteristic strata among those using alectinib postcrizotinib progression (N=207)
Characteristics
Treatment setting
Nonacademic
Academic
Physician specialty
Hematology/oncology
Medical oncology
Age
,65 years
$65 years
Race/ethnicity
White
Asian
Other
Smoking status
Current smoker
Former/never/passive smoker
BMI
Underweight
Normal
Overweight
Obese
CCI
0
1
2+
ECOG
0–1
2+
Unknown
Prior chemotherapy
No prior chemotherapy
Prior chemotherapy

N

Complete
response (%)

Partial
response (%)

Stable
disease (%)

Progressive
disease (%)

102
105

9.0 (8.8)
5.0 (4.8)

57.0 (55.9)
68.0 (64.8)

28.0 (27.5)
19.0 (18.1)

8.0 (7.8)
13.0 (12.4)

109
98

7.0 (6.4)
7.0 (7.1)

66.0 (60.6)
59.0 (60.2)

28.0 (25.7)
19.0 (19.4)

8.0 (7.3)
13.0 (13.3)

133
74

11.0 (8.3)
3.0 (4.1)

77.0 (57.9)
48.0 (64.9)

32.0 (24.1)
15.0 (20.3)

13.0 (9.8)
8.0 (10.8)

113
37
57

11.0 (9.7)
2.0 (5.4)
1.0 (1.8)

68.0 (60.2)
31.0 (83.8)
26.0 (45.6)

25.0 (22.1)
2.0 (5.4)
20.0 (35.1)

9.0 (8.0)
2.0 (5.4)
10.0 (17.5)

24
183

2.0 (8.3)
12.0 (6.6)

12.0 (50.0)
113.0 (61.7)

4.0 (16.7)
43.0 (23.5)

6.0 (25.0)
15.0 (8.2)

6
102
80
19

0.0 (0)
8.0 (7.8)
5.0 (6.3)
1.0 (5.3)

3.0 (50.0)
65.0 (63.7)
48.0 (60.0)
9.0 (47.4)

2.0 (33.3)
18.0 (17.6)
20.0 (25.0)
7.0 (36.8)

1.0 (16.7)
11.0 (10.8)
7.0 (8.8)
2.0 (10.5)

96
62
49

8.0 (8.3)
5.0 (8.1)
1.0 (2.0)

61.0 (63.5)
37.0 (59.7)
27.0 (55.1)

18.0 (18.8)
14.0 (22.6)
15.0 (30.6)

9.0 (9.4)
6.0 (9.7)
6.0 (12.2)

102
10
95

7.0 (6.9)
0.0 (0)
7.0 (7.4)

66.0 (64.7)
3.0 (30.0)
56.0 (58.9)

25.0 (24.5)
3.0 (30.0)
19.0 (20.0)

4.0 (3.9)
4.0 (40.0)
13.0 (13.7)

163
44

12.0 (7.4)
2.0 (4.5)

98.0 (60.1)
27.0 (61.4)

42.0 (25.8)
5.0 (11.4)

11.0 (6.7)
10.0 (22.7)

P-value
0.173

0.435

0.576

0.001

0.074

0.811

0.569

0.009

0.006

Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ECOG, Eastern Cooperative Oncology Group.

OncoTargets and Therapy 2018:11

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

79

Dovepress

DiBonaventura et al

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 98.142.124.101 on 18-Jan-2018
For personal use only.

Table 5 Frequency and reasons for dosage modification among
patients using alectinib post-crizotinib progression (N=207)
Modification
category

Reason

N (%)

Discontinuation
(N=29; 14.0%)

Disease progression
Death
Patient request
Other
Toxicity
Disease progression
Patient request
Patient request

12 (41.4)
9 (31.0)
5 (17.2)
3 (10.3)
7 (77.8)
1 (11.1)
1 (11.1)
1 (100.0)

Dose reduction
(N=9; 4.3%)
Dose interruption
(N=1; 0.5%)

specific adverse events included fatigue (N=4), hepatotoxicity (N=2), bradycardia (N=1), and edema (N=1).

Discussion
The objectives of this study were to examine the real-world
usage and clinical outcomes among patients with ALK+
NSCLC who were treated with alectinib after progressing on
crizotinib as their first ALK inhibitor. The sample characteristics of our study patients vs those of clinical trials patients
emphasize the differences between these two environments.
The alectinib sample in our study was ~10 years older, had
fewer Asian respondents, more African-American and
Hispanic respondents, had a more diverse histology (clinical
trials were almost exclusively adenocarcinoma), had more
current smokers, and had poorer functional status based on
ECOG measures than clinical trial samples.28,29 Additionally,
many alectinib patients were managed by a hematologist/
oncologist and in the private practice setting. Although not
alectinib specific, recent real-world data studies of ALK+
NSCLC patients suggested similar demographic (age, sex)
and health history (smoking status) findings as reported
here.32,33 These results suggest that the patients prescribed
alectinib immediately after crizotinib progression are more
demographically diverse than those enrolled in clinical trials,
which could have implications for clinical outcomes and
experiences with safety/tolerability events.
Rates of brain metastases in our study vis-à-vis published
literature deserve specific comment. Some real-world studies
have reported brain metastatic rates over 50%,34 which is similar to that reported in clinical studies.28–30 However, other realworld studies have estimated rates closer to 20%–30%.33,35–37
These numbers are still higher than those reported in our
sample in which 12% of patients had brain metastases at
the end of crizotinib/initiation of alectinib. Although it
is unknown what could cause the discrepancy, there are
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several possibilities. First, the follow-up time (as well as the
timeframe that constituted “baseline”) was slightly shorter
in the present study (eg, relative to Betts et al33); thus, there
was less time for a brain metastasis to manifest. Secondly,
our patient population was generally older than the available
clinical data, and research has suggested that the incidence
of brain metastases in older patients is lower than that in
younger patients.38 Recent studies have suggested that only
47% of brain metastases are symptomatic39 representing a
possible source of underdiagnosis of brain metastases that is
disproportionately more common in smaller practices than
larger academic centers. Most of the patients in this study
were treated in smaller private practices, which could have
contributed to the lower rates of brain metastasis. Undoubtedly, more research is necessary, though substantial clinical
data suggest the importance of brain metastases in the ALK+
NSCLC patient population.24,40
The observed response rates were generally similar in
our study to clinical trial results and, to a certain degree,
even more favorable.28–30 However, in some cases these
response rates differed significantly by the characteristics
of the patients. Asian patients (vs non-Asian/non-White
patients), former/passive/never smokers (vs current smokers),
and patients with better functional status (vs patients with
poorer functional status), all reported better response rates.
Nevertheless, it should be noted that for all strata, response
rates were objectively high and, due to small sample sizes,
caution should be exercised when interpreting the comparisons across groups. Further, the RECIST criteria were not
used to define response in this real-world study; rather, the
oncologist determined response based on information in the
patient’s chart.
Finally, the results suggest that alectinib was well tolerated in real-world clinical practice. Discontinuation was
relatively uncommon over the study period (14%) and
when it occurred it was mostly due to disease progression;
no discontinuation due to adverse events was observed.
Dosage reductions and dosage interruptions were even less
common. Fatigue was the most common safety/tolerability
event that led to dose modifications. However, it should be
noted that the observation time for our study (due to the recent
availability of alectinib) was less than that in clinical trials
(14–20 months for randomized controlled trials vs 10 months
for our study; Table 2).

Limitations
Most of the research questions were descriptive in nature,
without clear threats to internal validity. However, the
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method and the nature of the sample source may be a threat
to the external validity. Only members of an Internet panel
were eligible to join; these physicians (and, by extension,
perhaps their patients) may differ from broader oncologist
population. The selected panel did have a large representation with the intent to minimize this bias. Another threat to
validity was the chart selection method. Although physicians
were asked to select their most recent patients, physicians
could have selected charts preferentially, which may have
biased the sample of patients. Finally, the RECIST criteria
were not used to determine response to treatment in this
real-world study.

Conclusions
This retrospective chart review study is the first to document
the real-world usage and clinical outcomes of patients with
ALK+ NSCLC who are treated with alectinib after experiencing progression on crizotinib as their first ALK inhibitor.
Substantial differences were observed between the real-world
sample and the samples of alectinib clinical trials; our study
suggested (consistent with other real-world data studies
on ALK+ NSCLC patients more broadly31,32) that patients
using alectinib in clinical practice are older, more racially/
ethnically and histologically diverse than those samples in
published trials. Nevertheless, response rates are generally
high and similar to those reported in clinical studies, though
there is some variation by patient characteristics. In addition, alectinib was well tolerated in clinical practice with
no discontinuations or dose interruptions and very few dose
reductions due to adverse events.
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